Welcome to our dedicated page for Amylyx Pharmaceuticals SEC filings (Ticker: AMLX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) SEC filings page on Stock Titan provides access to the company’s official disclosures filed with the U.S. Securities and Exchange Commission. For a clinical-stage biopharmaceutical issuer focused on neurodegenerative and endocrine diseases, these documents are a primary source of information on financial condition, capital raising, and material program decisions.
Current reports on Form 8-K are especially relevant for AMLX. Recent 8-K filings have covered quarterly financial results, underwritten public offerings of common stock, and key R&D updates such as the decision to discontinue the ORION program of AMX0035 in progressive supranuclear palsy after Phase 2b results did not show differences versus placebo. Other 8-Ks describe the entry into underwriting agreements for equity offerings and the intended use of proceeds, including avexitide commercial readiness, research and development, working capital, and other general corporate purposes.
Investors can also use this page to track registration statements and prospectus supplements referenced in 8-Ks, which outline the terms of offerings and the securities being issued, as well as ongoing reporting obligations that detail research and development focus, cash runway expectations, and risk factors tied to Amylyx’ pipeline programs.
Stock Titan enhances these filings with AI-powered summaries that highlight the most important points from lengthy documents, helping users quickly understand items such as results of operations, material program changes, or capital structure updates. Real-time ingestion from the SEC’s EDGAR system means new Amylyx filings, including 8-Ks and other periodic reports, appear promptly, while structured views of exhibits and key sections make it easier to locate information on topics like avexitide development, AMX0035, AMX0114, and AMX0318.
For those analyzing AMLX stock, this page serves as a focused hub for reviewing the company’s regulatory record, understanding how it communicates material events, and seeing how financing activities align with its clinical-stage strategy.
AMLX filed a Rule 144 notice for a planned insider stock sale. The filing covers the proposed sale of 1,995 shares of the issuer’s common stock through Morgan Stanley Smith Barney LLC on NASDAQ, with an aggregate market value of $26,972.40 as of the filing details.
The shares to be sold were acquired on January 16, 2026 via an exercise of stock options paid in cash on the same date. The notice also lists prior sales of the issuer’s common stock during the past three months for the account of Justin Klee, including 136,193 shares sold on January 15, 2026 for gross proceeds of $1,849,860.26 and 7,715 shares sold on January 6, 2026 for gross proceeds of $85,589.44.
AMLX1,974 common shares through Morgan Stanley Smith Barney LLC on the NASDAQ, with an aggregate market value of $26,688.48 based on the figures provided. The shares relate to an exercise of stock options on 01/16/2026, paid for in cash and acquired from the issuer on the same date.
The notice states that AMLX had 109,819,569 shares of common stock outstanding. Over the prior three months, sales for Cohen’s account included 136,193 common shares on 01/15/2026 for gross proceeds of $1,850,794.52 and 7,715 common shares on 01/06/2026 for gross proceeds of $85,596.38. By signing, the seller represents that he is not aware of undisclosed material adverse information about the issuer.
An insider of Amylyx filed a Form 144 notice outlining a planned sale of company stock. The filing covers up to 136,193 common shares to be sold through Morgan Stanley Smith Barney LLC on or after January 15, 2026 on the NASDAQ, with an indicated aggregate market value of $1,916,235.51. These shares were acquired the same day through a cash exercise of stock options. The filing also notes that 109,819,569 common shares were outstanding and that the same individual sold 7,715 shares of common stock for $85,596.38 on January 6, 2026. The signer represents that they are not aware of any material adverse, nonpublic information about Amylyx.
An insider of the company with ticker AMLX has filed a notice of intent to sell 136,193 shares of common stock through broker Morgan Stanley Smith Barney LLC on or about 01/15/2026, with an indicated aggregate market value of $1,916,235.51. The filing notes that these shares were acquired on the same date via a cash exercise of stock options from the issuer.
As context, the filing lists 109,819,569 shares of common stock outstanding and discloses that Justin Klee sold 7,715 shares of common stock on 01/06/2026 for gross proceeds of $85,589.44 during the prior three months. The seller also represents that they are not aware of any undisclosed material adverse information about the issuer’s current or prospective operations.
Amylyx Pharmaceuticals director reports stock gift. Director George M. Milne Jr filed a Form 4 showing a bona fide gift of 17,780 shares of Amylyx Pharmaceuticals, Inc. common stock on January 12, 2026. The shares were transferred for no consideration, meaning he did not receive payment for them. After this gift, he directly beneficially owned 812,881 shares of the company’s common stock.
Amylyx Pharmaceuticals, Inc. Chief Financial Officer James M. Frates reported an automatic sale of common stock. On January 6, 2026, he sold 3,326 shares of Amylyx common stock at a weighted average price of $11.1106 per share. According to the filing, these shares were sold solely to cover tax withholding obligations arising from the vesting of restricted stock units, and the sale was not at his discretion.
After this transaction, Frates directly beneficially owned 177,104 shares of Amylyx common stock. He also had indirect holdings through trusts, including 100,000 shares held by the JAMES M. FRATES 2025 GRAT No. 1 and additional blocks of 15,459 shares and 11,072 shares in other family trusts. For these trust holdings, he serves as trustee and disclaims beneficial ownership except to the extent of any pecuniary interest.
Amylyx Pharmaceuticals, Inc. director and Co-Chief Executive Officer Joshua B. Cohen reported an automatic sale of common stock. On January 6, 2026, he sold 7,715 shares of Amylyx common stock at a weighted average price of $11.0948 per share. According to the disclosure, these shares were required to be sold to cover tax withholding obligations arising from the vesting of restricted stock units, and the sales were automatic and not at his discretion.
After this transaction, Cohen beneficially owned 3,317,632 shares of Amylyx common stock, held directly.
Amylyx Pharmaceuticals Co-Chief Executive Officer Justin B. Klee reported an automatic sale of 7,715 shares of common stock on January 6, 2026. The shares were sold at a weighted average price of $11.0939 per share to cover tax withholding obligations arising from the vesting of restricted stock units, and the sale was not made at his discretion.
After this tax-related sale, Klee beneficially owned 3,317,586 shares of Amylyx Pharmaceuticals, Inc. common stock directly.
Amylyx Pharmaceuticals reported that it has selected AMX0318, a long-acting GLP-1 receptor antagonist, as a new development candidate for treating post-bariatric hypoglycemia and other rare diseases. AMX0318 was discovered through a research collaboration with Gubra A/S, which specializes in peptide-based drug discovery and preclinical research.
Under this collaboration, Gubra is eligible to receive more than $50 million in success-based development and commercialization milestone payments, plus mid-single digit royalties on worldwide net sales if AMX0318 progresses successfully. The selection and handover of the development candidate immediately triggers $4 million in milestone payments to Gubra.
Amylyx also updated its corporate presentation for use with investors and analysts, furnishing the new presentation as Exhibit 99.1.
Amylyx Pharmaceuticals (AMLX) filed its Q3 2025 report, showing a smaller quarterly loss as it reorients around its clinical pipeline. Net loss was $34.4 million versus $72.7 million a year ago, with basic and diluted net loss per share of $0.37 versus $1.07. Operating expenses fell to $36.0 million from $76.1 million, reflecting the absence of prior-year charges and reduced spend on discontinued programs.
Liquidity strengthened markedly. As of September 30, 2025, cash and cash equivalents were $225.2 million and marketable securities were $118.8 million. The company completed two underwritten offerings in 2025: 19.7 million shares at $3.50 for net proceeds of $65.5 million in January and 20.1 million shares at $10.00 for net proceeds of $190.7 million in September. Shares outstanding were 109,819,569 as of October 27, 2025.
Amylyx reports no product revenue in 2025 following the RELYVRIO/ALBRIOZA discontinuation. The company is advancing key programs: the Phase 3 LUCIDITY trial of avexitide in post-bariatric hypoglycemia (recruitment completion expected in the first quarter of 2026 with topline data in the third quarter of 2026) and the Phase 1 LUMINA trial of AMX0114 in ALS, with early cohort enrollment completed and initial data planned for scientific meetings.